Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEPOT Study
NCT04911361Phase 4Completed
- Sponsor
- Research Insight
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ozurdex in dry eye syndrome (DED) (2 arms), sponsored by Research Insight. Primary endpoint: Effect of dexamethasone insert at 2 weeks. Started Aug 2021; status: completed.
02
Drugs
ozurdex
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04911361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911361.